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Abstract 
Objectives: The purpose of this paper is to systematically examine the literature regarding 
primary care physicians' knowledge and practice style concerning prostate cancer screening. I 
will then use the information to develop a research plan to assess physician practice styles, 
beliefs, and knowledge of recent guidelines and scientific evidence regarding prostate cancer 
screenmg. 
Methods: I conducted a systematic evidence review to determine whether American primary 
care physicians are using shared decision-making when doing prostate cancer screening and 
which clinical practice guidelines (CPGs) they are aware of. I used a Medline search. Cross-
sectional studies were included in the review. Randomized controlled trials, cohort studies and 
case-control studies would have been accepted except none were found. The main outcomes of 
interest were physicians' prostate cancer screening style specifically if they do pretest counseling 
(including shared decision-making), and knowledge of prostate cancer screening guidelines. 
Shared decision-making was defined as physicians doing prescreening discussions of the risks 
and benefits of prostate cancer screening and allowing their patients to participate in the decision 
whether or not to proceed with screening to the level the patient desired. 
Results: Seven studies were included in the final review, none were done since the most recent 
guideline updates issued in 2008 and 2009 and none looked at knowledge of recent evidence 
from two large randomized controlled trials (RCT) on mortality benefit of PSA screening that 
were published in March of 2009. Several themes emerged from the literature review of studies 
published since 2000. It showed that between 60% and I 00% of physicians report using shared 
decision-making. The 100% was from a focus group study, whereas in surveys between 66% 
and 99% of physicians report using shared decision-making. Physicians with knowledge of the 
guidelines or the unclear evidence of benefit are more likely to use shared decision-making than 
those without the knowledge. And between 0% and 33% of men age 50 and over are being 
screened for prostate cancer without a prescreening discussion of risks and benefits. No studies 
compared knowledge of guidelines to practice style. 
Conclusion: Primary care physicians with greater knowledge of the insufficient evidence for 
prostate cancer screening are more likely than those lacking knowledge to be practicing shared 
decision-making. Since all of the studies were done prior to 2009, it is not clear whether 
physicians have knowledge of the newest CPGs and randomized-control trial evidence for 
prostate cancer screening. Yet, the results of this review show that knowledge of the latest 
developments is likely to influence practice. 
Our research study is designed to assess the knowledge of the newest evidence and guidelines 
and the effect this has had on physician belief of benefit of prostate cancer screening. The 
primary outcomes will be knowledge of the mortality studies and current guideline, reported 
influence of the 2009 RCTs of prostate cancer screening on practice style, any association 
between knowledge of the RCTs or guidelines and belief of benefit of prostate cancer screening, 
and any association between knowledge of the mortality studies on practice style. We will also 
assess the way physicians report learning about the RCTs and any association between reported 
knowledge and correct knowledge answers with method oflearning about the RCTs. 
Introduction and Background 
Prostate Cancer Prevalence 
Wedlake 4 
Prostate Cancer is the second most common cancer death in men in the United States. 
One in six men will develop prostate cancer at some point in their life. It is estimated that 27,360 
men will die from prostate cancer in 2009 and 192,280 will be diagnosed with prostate cancer. 
Despite its high prevalence 80% of men who are diagnosed with prostate cancer are diagnosed 
with localized disease, which has a I 00% 5-year survival rate. Prostate cancer had an overall 
99.7% 5-year survival rate from 1999 to 2005. 1 Prostate Cancer is often described as a cancer 
men die with instead of a cancer men die from. 
Screening for Prostate Cancer 
Screening for prostate cancer is done either with prostate-specific antigen (PSA) alone or 
PSA combined with digital rectal exam (DRE). Unfortunately, neither the PSA nor the DRE 
tests are specific. PSA levels can be elevated for many reasons besides prostate cancer and can 
remain normal in some men with cancer.2 Up to 38% of prostate cancers occur in men with 
PSA levels below 4ng/ml. The PPV of PSA is approximately 25 .I%, from a pooled analysis of 
over 47,000 males (from 14 studies) aged 40-92 having a 10% prevalence ofPSA >4ng/ml3 The 
high false positive rate, 3 to 4 out of every 4 or 5 men with elevated PSA levels( above 4ng/ml), 
can lead to many unnecessary work-ups.3 
A variety of alterations have been considered for use of the PSA test to improve its 
accuracy; unfortunately none have been widely accepted due to unclear evidence of benefit. At 
least eight different versions ofPSA testing have been tried. The PSA density, PSA Velocity, 
rate-specific PSA cutoffs, increased intervals for PSA screening, free PSA, complexed PSA and 
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age-specific PSA cutoffs have not been proven to improve the sensitivity and specificity of PSA. 
Each method has its advantages and its disadvantages. Some are more sensitive, others more 
specific. None have been shown to increase both sensitivity and specificity compared to normal 
PSA screening?· 4 
The accuracy of digital rectal exam (DRE) has been shown to vary among 
providers. Overall, it is thought to be more specific than it is sensitive. The test depends on the 
physician's impression and has been shown to have a PPV of28% in a pooled analysis of 14 
studies meaning that 72% of patients with a positive DRE will not be found to have cancer on 
biopsy.5 
The benefits of the PSA test as a screening tool is debatable. It is clear that the PSA test 
can detect some asymptomatic prostate cancers and thus lead to earlier treatment. It remains 
unclear whether earlier detection and treatment leads to lower morbidity and mortality when 
done at a population level. Two large randomized trials, the Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial (PLCO) and the European Randomized Study of Screening for 
Prostate Cancer (ERSPC) published their intermediate results in March of2009. Both had hoped 
to clarify the benefit ofPSA screening. The PLCO study showed no significant mortality 
difference between the screened and unscreened group6 ; and the ERSPC study showed a 
modest decrease in mortality of the screening group. The ERSPC study found that 141 0 men 
would need to be screened and 48 men treated for prostate cancer to prevent one prostate cancer 
death. 7 Both studies had significant limitations. One of the most important limitations of the 
PCLO study is the contamination of the control groups with men who had PSA tests done 
outside the protocol. 8• 9 The ERSPC did not have a standardized screening protocol between 
testing sites. PSA cutoffs ranged from 3ng/ml to 4ng/ml and some locations did DRE in addition 
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to PSA depending on PSA value. 7• 9 Both studies are continuing on and will hopefully give 
more information in the future, especially concerning the harms of PSA screening. 
Prostate Cancer Diagnosis 
Prostate cancer is diagnosed by biopsy. Biopsies are done after a patient has an abnormal 
PSA or DRE. Transrectal biopsies of the prostate are done and 8 to 19 core samples are taken. 10 
Higher numbers of core samples can lead to cancer detected at earlier stages.4 Based on the 
findings from the biopsy the cancer is assigned a Gleason score and staging is done with imaging 
if deemed necessary by Gleason score. 10 
Prostate Cancer Treatment 
Prostate cancer can be treated by a variety of methods. Depending on the Gleason score 
and stage of the cancer, patients have a variety of options. Eighty percent of prostate cancers are 
localized at diagnosis allowing patients to have multiple choices for treatment.4 Most patients 
are asked to choose between active surveillance, radical prostatectomy, and radiation (external 
beam or brachytherapy). Androgen deprivation therapy is also used for some patients. All have 
risks and benefits. Radical prostatectomy is the most common intervention chosen to treat 
localized prostate cancer. 2 
All of the treatment interventions except active surveillance are associated with a risk of 
bowel dysfunction, sexual dysfunction and urinary incontinence. The risk of developing 
incontinence varies from 2 to 50% depending on the intervention with the highest risk associated 
. h 2 w1t prostatectomy. Sexual dysfunction is even more common affecting between 20 and 92% 
of patients. The highest risk is with androgen deprivation and prostatectomy. Bowel 
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dysfunction varies from 4-35% with external beam radiation and brachytherapy having the 
highest risk.2 
The stage of the prostate cancer helps determine whether active surveillance is a viable 
option or not. Patients choosing active surveillance have their PSA levels checked every 3 to 6 
months, and have repeat DRE and biopsies done as needed. 11 In a study by Wong et allooking 
at SEER (Surveillance Epidemiology and End Results Medicare database) data, choosing active 
surveillance over treatment was shown to be associated with decreased long term survival for 
men between ages 65 and 75. 12 A review ofliterature done by Bastian et al in 2009 shows 
active surveillance to be a viable option for patients with a low Gleason score less than or equal 
to 6 and with organ confined disease. The studies in the review showed that active surveillance 
was not associated with increased mortality compared to treatment when done in the low risk 
group. 11 
A retrospective cohort study by Albertson et al in 2005 looking at the risk of mortality by 
Gleason score showed that patients with a low Gleason score (2-4) have a minimal risk of dying 
from prostate cancer over 20 years (6 deaths per 1000 person-years). The higher the Gleason 
score the more likely the chance of death. Men with a Gleason score between 8 and 10 had 121 
deaths per 1000 person-years. 13 There are several randomized controlled trials currently going 
on to look at which choice of treatment is most beneficial for the variety oftrunor grades. The 
PIVOT trial (prostate cancer intervention verses observation therapy), which should be 
completed in 2010, specifically addresses active surveillance as an option. 14 
The Dilemma 
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With this significant list of complications it is important to consider whether the benefits of 
screening and early treatment outweigh the harms. Many prostate cancers are slow growing and 
will not lead to death. The lifetime risk of dying from prostate cancer is only 3.4% despite a 
15.9% lifetime risk of developing prostate cancer. I It is estimated that a national prostate 
screening program would cost around twenty billion dollars without the cost of treating any 
I. 
cancers detected. ' The technology is present to both detect and treat prostate cancer but not to 
determine which cancers will progress and which cancers will not progress. This leads the 
medical community to both over-detect and over-treat. Over-detection and overtreatment have 
more than just financial costs; there are psychological consequences of having false positive tests 
and health risks of being over-treated. The rate of over-detection is as high as 56%.11 
Given the dilemma physicians are not supposed to screen patients for prostate cancer 
but are instead supposed to counsel them on the risks and benefits of screening. Patients should 
choose whether or not screening is right for them. Hoffman eta! showed in the DECISIONS 
Study that while health care providers provided prescreening discussions the discussions failed to 
meet the criteria for shared decision making. The information was not unbiased or balanced and 
patients were often not asked for their preferences. 16 If health care providers are unable to fully 
educate their patients on the risks and benefits of screening then, is the medical community 
breaking its oath to "first do no harm" by screening for prostate cancer in asymptomatic men? 
Guidelines 
Because of the debate over whether screening should be done and the increasing use of 
evidence based medicine in clinical practice, many different organizations have released 
guidelines regarding prostate cancer screening. In fact most of the organizations have updated 
their guidelines in 2008 or 2009 as a result of the changing body of evidence on the utility of 
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prostate cancer screening. "No major scientific or medical organizations, including the 
American Cancer Society (ACS), American Urological Association (AUA), US Preventive 
Services Task Force (USPSTF), American College of Physicians (ACP), National Cancer 
Institute (NCI), American Academy of Family Physicians (AAFP), and American College of 
Preventive Medicine (ACPM) support routine testing for prostate cancer at this time." from the 
American Cancer Society "Can Prostate Cancer Be Found Early?" 10 
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Systematic Review Table 1 
Or~anization Guideline 
American Cancer Recommends making an offer of screening to men over age 
Society (ACS) 50 who have at least a 10 year life expectancy, only after 
having a discussion about the benefits and limitations of 
screening. It recommends starting at age 45 for men at higher 
risk. No suggested age to stop screening. Updated 3/5/200810 
American Urological Recommends discussing screening with men at age 40, if they 
Association (AUA) wish to be screened doing a baseline PSA and DRE at age 40. 
It also emphasizes use of PSA velocity prior to proceeding to 
biopsy. Does not give age cut offfor stopping but does state 
screening is most beneficial for men with at least a 1 0-year 
life expectancy. Updated 4/28/200917 
United States Preventive "* The USPSTF concludes that the current evidence is 
Services Task Force insufficient to assess the balance of benefits and harms of 
(USPSTF) prostate cancer screening in men younger than age 7 5 years. 
Grade: I statement. 
* The USPSTF recommends against screening for prostate 
cancer in men age 75 years or older. Grade: D 
recommendation. 
Suggested practice: Given the uncertainties and controversy 
surrounding prostate cancer screening in men younger than 
age 7 5 years, a clinician should not order the PSA test without 
first discussing with the patient the potential but uncertain 
benefits and the known harms of prostate cancer screening 
and treatment. Men should be informed of the gaps in the 
evidence and should be assisted in considering their personal 
preferences before deciding whether to be tested." Updated 
August 2008 18 
American College of "There is currently insufficient evidence to recommend 
Preventive Medicine routine population screening with digital rectal examination 
(ACPM) (DRE) or prostate-specific antigen (PSA). men should be 
given information about the potential benefits and harms of 
screening and limits of current evidence in order to make an 
informed decision about screening. Discussion about 
screening should occur annually, during the routine periodic 
examination, or in response to a request by the patient." 
Updated Feb 2008 15 
American Academy of The AAFP concludes that the current evidence is insufficient 
Family Practice (AAFP) to assess the balance of benefits and harms of prostate cancer 
screening in men younger than age 75 years. The AAFP 
recommends against screening for prostate cancer in men age 
75 years or older. Updated December 2008 19 
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Adopting New Evidence 
The incorporation of new evidence into clinical practice is influenced by many factors. 
One influence is how the new evidence is perceived.Z0 How and when physicians hear about 
the evidence or guidelines can affect how it is perceived. Did they hear about it from the news, a 
patient, a colleague, a formal CME presentation or an editorial? If they are hearing about from 
the news or a patient are they looking at the article or guideline themselves? Little research has 
been done to show how the media affects physician practice.21 
The dispersion and marketing of new evidence is probably the most important thing 
affecting its incorporation. Approximately 15% to 20 %of physicians need to accept new 
evidence and change their practice before new evidence has enough momentum to spread on its 
own.20 Until, the first 20% of physicians have not only heard of but also accepted the new 
evidence it needs to be marketed. The ALLHAT dispersion study showed the value of marketing 
important research results and guidelines in order to increase acceptance.22 
New research once disseminated to clinicians can have varying levels of effect. If it 
decreases ambiguity, has clear benefit, and aligns with protocols, history, values or beliefs then 
new evidence is likely to be adopted quickly.Z0 The personal characteristics of the provider also 
influence adoption of new evidence. Five categories of individuals have been defined to explain 
personal adoption behavior: innovators, early adopters, early majority, late majority, and 
laggards. The categories are based on their place along the normal curve (1,2, and 3 standard 
deviations). Which category an individual provider falls in affects the speed at which they are 
likely to adopt new evidence. Contextual factors also affect adoption of new evidence. 
Environments can either promote or discourage individuals from adopting new evidence, which 
may differ from the current standard of care. 20 
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Pathman has described a model to encompass all of the stages for clinician adoption of 
new CPGs: physician awareness, agreement, adoption and adherence.23 We have already 
discussed many of the factors that can affect each stage of the pathway. It is important to realize 
that information alone does not typically change physician behavior.23 
The influence of prostate cancer screening guidelines and the mortality studies (ERSPC 
and PCLO) depends on several important barriers. First, the guidelines are not consistent. The 
lack of consensus lowers the likelihood of any guideline being followed. The content of some of 
the guidelines are not specific, leaving physicians to determine what the risks and benefits of 
prostate cancer screening are.24 The results of the mortality studies could potentially clarify the 
benefit of PSA screening. Unfortunately the two studies had differing interim results and have 
been subject to significant criticisms questioning the validity of their results. Despite these 
barriers the guidelines and mortality studies were well disseminated when released, being 
reported by most major news organizations and several large professional organizations.25 The 
broad dissemination increases the likelihood that some physicians will incorporate them into 
h . . 'f h . h h 20 23 t e1r pract1ce 1 t ey agree WJt t em. · 
Physician Practice 
All of the guidelines tell primary care physicians to help their patients make an informed 
choice about prostate cancer screening. How this translates into practice is influences by a 
variety offactors. A study of 1369 primary care physicians in Washington State showed that the 
majority (67%), routinely recommended PSA screening. Reimbursement, physician age, and 
male sex of physician all increase the likelihood of ordering a PSA test. 26 For physicians to 
follow the guidelines and counsel patients they must first understand the risks and benefits 
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themselves and have the time or tools needed to explain them to their patients. In a study of 
Vermont primary care physicians, physician belief that the evidence for prostate cancer 
screening is not strong led to longer discussions and lower use of PSA screening. 27 Another 
study supported the evidence that a physician's interpretation of the utility of PSA screening 
affects his/her likelihood of not only discussing PSA screening with his/her patients but whether 
he/she would try to persuade patients to have the screening done?8 
Introduction to Research Project and Systematic Review 
To determine if the new guidelines and the new evidence on PSA testing have affected 
provider practice, knowledge of past practice is needed. We have done a systematic review of 
literature looking at provider screening practices with PSA since 2000 in the United States. The 
focus on provider practice since 2000 was done because by the year 2000 several guidelines 
recommended counseling on risks and benefits over routine screening for prostate cancer 
existed.29 In addition, provider practice is being increasingly affected by clinical practice 
guidelines (CPG), with 3 8% percent of primary care physicians reporting that CPGs have a large 
influence on their practice in 2005 compared to only 24% in 2000.30 The growing influence of 
CPGs also increases the likelihood that physicians' practices could be affected by changes in the 
guidelines. 
While several studies have been published since the guidelines started to change in 2008, 
none of the data collection was done after that time.27• 28• 31 -37 The results of the systematic 
review were used to develop a study design for a cross sectional survey to determine the reported 
association between reported physician practice regarding prostate cancer screening and the 
mortality study results and current CPGs. The study will show if physicians know about the new 
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guidelines and evidence? Do they report changing their practice as a result? Do physicians 
believe prostate cancer screening has more benefit than harm? By determining what providers 
are reporting as their current practice, assessing their knowledge of CPGs and the mortality 
studies, and level through this study, we hope to show whether an association exists between the 
mortality studies and CPGs and increased counseling of both the risks and benefits of prostate 
cancer screening. 
Systematic Review of the Literature on Provider Practice 
Methods 
A systematic review of literature was done to answer several questions. What is current 
primary care practice regarding prostate cancer screening? Specifically are physicians providing 
their patients with the risks and benefits of prostate cancer screening prior to offering them test? 
Do physicians know the prostate cancer screening guidelines? A search on Medline was done 
using the MeSH terms: "Prostate Cancer", "Prostate specific antigen" and "Primary Health 
Care". The search was done on June 1, 2009 and returned 161 results. The results were limited 
to English language and publication after 2000, leaving 116 studies. No limitations were placed 
on study design for the initial search since few studies were expected to meet the inclusion 
criteria. Inclusion criteria were: all study types (except case report, editorial and reviews), men, 
prostate cancer, US physician prostate cancer screening practice, physician knowledge regarding 
prostate cancer screening, physician attitude or belief regarding prostate cancer screening. The 
exclusion criteria were: studies not focusing on provider use of PSA test, non-US based studies, 
research done before 2000, case reports, commentaries, reviews and letters. The review was 
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limited to studies involving US physicians since influences may be different on provider practice 
in other countries, which have a different system of providing medical care. It was limited to 
physicians since mid-level providers, nurse practitioners and physician assistants, are likely to 
have the same practice style as their supervising physician. Studies done only after the year 
2000 were included because by 2000 several organizations had clinical practice guidelines 
recommending physicians using shared decision making for prostate cancer screening. 
The 116 studies were evaluated by their abstract for relevance of study question. Thirty 
were found to have a relevant outcome or measurement and were further evaluated by the 
inclusion and exclusion criteria. Ten were excluded because they were either letters or review 
articles. Six were excluded because the research was done outside the United States. Five 
studies were excluded because the studies were done before 2000. 
Nine articles were included for full review. Two studies were excluded during full 
review. One of the studies was by Sorum et al. It evaluated the level of regret physicians in the 
US and France would feel if they failed to diagnose prostate cancer through screening. 37 It did 
not answer either study question. It neither evaluated whether or not physicians use prescreening 
discussion of risks and benefits nor did it evaluate whether physicians have knowledge of 
prostate cancer screening guidelines. A second study by Gonzalez et al, was excluded after full 
review for failure to answer either study question. It used NAMCS data to evaluated if patients 
were screened for prostate cancer during clinic visits by looking at claims information. 33 The 
data used was not able to say anything about physician screening style or knowledge of 
guidelines other than if patients above or below the recommended ages are being screened. At 
the end of the selection process, I proceeded to critically review 7 studies on provider practice 
related to prostate cancer screening. 
Systematic Review Figure 1. Quorum Table 
161 by Medline for MeSH "Prostate 
Cancer", "Prostate specific antigen" 
and "Primary Health Care" on june 1, 
2009 
l"""' ""'· "·' '" ... ' 
116 abstracts reviewed for relevance 
of study focus 
30 abstracts relevant and reviewed 
by inclusion/ exclusion criteria 
9 full article review 
7 studies included in final 
review 
45 Not English Or 
Published before 2000 
86 excluded for 
relevance of study focus 
10 for being review 
articles or 
letters/editorials, 6 for 
being not US based 
studies, 5 for being done 
before 2000 
2 excluded because 
they were not 
relevant to the study 
focus questions 
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Systematic Review Table 2 
Inclusion Criteria Exclusion Criteria 
Articles About: Articles that are: 
I. Men I. Non-English 
2. Prostate Cancer 2. Related to treatment. 
3. Screening 3. Related to cancers other than 
4. Physician Practice prostate. 
5. Knowledge, Attitudes, Value 4. Reviews, Editorials, case reports 
6. All study types except reviews, 5. Not done in the United States 
editorials and case reports. 6. Done before 2000 
7. Focus on patient reporting or 
patient characteristics 
All included studies were rated for quality on a scale of poor, fair, and good. A good 
study is not lacking any key elements, a fair study is lacking something but it does not have a 
fatal flaw, a poor study has a fatal flaw. A fatal flaw is a bias, which makes the validity of the 
results questionable. An example of a fatal flaw is a biased survey making the outcome of 
interest more likely based on the design of the questions. Each study was rated based on internal 
validity: selection bias, measurement bias, and confounding. Studies with a low risk of selection 
bias have randomized how they chose their study population or used exhaustive sampling of a 
population. Studies unlikely to have measurement bias will need to have validated their 
measurement tool and have a measurement tool with as little bias as possible. Studies which 
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adequately control for confounders in the study design or the analysis and report those 
confounders will receive a good for likelihood of confounders affecting the results. There are 
many things that are possibly confounders for prostate cancer screening practice style. Important 
confounders for studies to consider include age since personal risk increases as age increases, sex 
since men may feel more strongly about a cancer that is likely to affect them, and race since 
mortality risk differs among races. Another possible confounder is a history of prostate cancer in 
themself or a close friend or family member. It is also possible that a physician's practice 
setting, academic or community, may influence prostate cancer screening practice style since 
academically affiliated settings may have a higher emphasis on adherence to CPGs. 
Studies found to have fair or good internal validity were also rated on external validity. 
External validity will be assessed by generalizability of the results. A good study will have more 
than one type of primary care physician and a study population that is large and diverse enough 
to apply to most of the United States primary care physician population. 
Results of the Systematic Review 
Linder et al (2009l8 
In 2004, Linder eta! conducted a survey of 87 primary care providers in university-based 
family medicine clinics and six community health centers in Houston, TX. The survey was 
designed to assess physicians' use of prescreening discussions and rationale for why physicians 
either try to persuade or not persuade their patients to be screened if testing was refused. Sixty-
three of the physicians completed the survey and were included in the analysis (28 internists, 35 
family practitioners). Three others were excluded based on their specialty or practice type 
(urgent care and psychiatry). The questionnaire was developed using findings from other similar 
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studies to assist in the wording. It was checked for validity with interactive feedback from 3 
primary care providers (PCP). Internal validity was established by having a second question 
address the practice style in a different format. 
Results 
Forty-five (71%) of the providers were classified as D (discussing) and 13 were classified 
as ND (not discussing). Three additional providers reported they neither order nor discuss PSA 
tests. The majority of the discussing providers (25) said they would let patients decide after 
discussing the harms and benefits while 20 providers reported they recommend screening. Only 
36.8% (7) of the D providers who recommend screening report that they would try and persuade 
a man to have a PSA test done. Between 65.6 and 72% of discussing providers report that they 
are more likely to screen African American men and 80-96.3% report that they are more likely to 
screen men with a family history. 
Overall the study showed that the majority of PCP discuss the harms and benefits of PSA 
testing with their patients and that physicians who believe PSA is beneficial are more likely to 
try and persuade their patients than those who are unsure of its benefit. The study did not report 
differences in screening style based on provider characteristics nor did it report knowledge of 
prostate cancer screening guidelines. 
Quality, Strengths and Weaknesses 
The internal validity of the study is fair because selection bias and confounding may have 
occurred. The study population included family practitioners and internists in university clinics a 
single urban Texas setting. No information was given as to how the different clinics were 
chosen for inclusion allowing for the possibility of selection bias. The measurement tool, the 
survey, was clearly described along with how control for internal and external validity of the tool 
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was done. The open-ended question section was coded separately by two authors and then 
grouped into themes. The outcome measurement was clear and appropriate given the 
measurement tool. The statistical analysis was clearly described. A weakness was seen in the 
lack of reporting of controlling for potential confounders (race, age, sex, history of prostate 
cancer) between provider types (D vs. ND) 
The external validity was fair since the study population was limited to university clinics, 
which may not be applicable to community-based physicians. It did have both family practice 
and general internists in the sample; however, the sample size was small. 
Pendelton et al (2008l 5 
A 27-item questionnaire was sent to PCP in 2 Florida counties in 2004. A total of264 
physicians were randomly selected after being identified through local medical societies. 
Twenty physicians completed the survey in response to the email invitation and another 85 
completed the survey after an in-person visit. The study population included a diverse group of 
primary care physicians in different practice settings. Fifty percent were connected to a 
University and 58% were family practitioners. Four percent were black and 68% were white. 
The study was designed to determine physician knowledge of prostate cancer and their attitude 
toward prostate cancer screening. The survey was created based on current accepted literature 
and was evaluated by a small group of diverse and experienced physicians including family 
practice, internal medicine, radiation oncology and urology. The survey was then modified 
based on their feedback. 
Results 
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A total of 104 physicians completed the survey (39%). Forty-six percent of physicians 
report recommending prostate cancer screening to more than 75% of their patients over age 50. 
The overall score on the knowledge survey was 66% with providers who had either a high 
percentage of minorities in their practices or practices located in urban areas having higher 
scores than those with fewer minorities or rural practice locations. Only 39% of physicians knew 
that the PSA test is "highly sensitive" but not specific. A lack of knowledge of the weaknesses 
of the test may impede their ability to explain the risks and benefits of prostate cancer screening 
to their patients. Seventy-five percent of physicians knew that African decent and family history 
are risk factors for prostate cancer. Sixty-six percent of physicians reported that prostate cancer 
screening is effective and 64% felt that screening with PSA is beneficial. Only 53% offer 
screening to minorities while 70% offer it to men with a family history. Physician knowledge 
did not correlate with their reported practice in regards to screening higher risk men. Knowledge 
of prostate cancer screening guidelines was not assessed. 
Quality, Strengths and Weaknesses 
The internal validity of the study is poor. Measurement bias is a significant concern. The 
measurement tool was evaluated by a variety of provider types and altered based on their 
feedback. While it is a strength of the survey tool that primary care providers, urologists and 
oncologists were involved in its development, the final version was not assessed for validity 
prior to sending it out. The questions show bias toward higher screening and knowledge of 
statistics related to prostate cancer. The result is misclassifying physicians who are following the 
guidelines, which recommend sharing the risks and benefits of screening with patients and 
allowing patients to choose whether or not they are screened. The knowledge answers deemed 
correct and incorrect are also of concern. An example of this is the question that voiding 
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symptoms are one of the first symptoms of prostate cancer. The answer deemed correct was 
false because prostate cancer is usually asymptomatic. The question is poorly worded because 
once prostate cancer is symptomatic urinary tract symptoms, impotence and pain can occur. 10 It 
also said that the PSA is highly sensitive when at a cutoff of 4ng/dL it has a sensitivity of 72% 
(range 67% - l 00% ).3 The analysis was also felt to have bias because the answers ofthe survey 
were interpreted to show more information than actually asked. Physicians were asked to report 
the proportion of male patients over age 50 for which they screen or recommend screening for 
prostate cancer. Physicians were deemed not to be following guidelines if they did not screen or 
recommend screening for their patients. It did not ask which guidelines they may know or be 
following. This allowed for misclassification of physicians who are following the USPSTF and 
other guidelines, which recommend discussing the risk and benefits of screening with patients 
instead of recommending or ordering PSA. The analysis did adjust for possible confounders 
including age, race, degree, practice type, practice setting. Selection bias is also unlikely, since 
the study population was randomly selected and included a diverse group of providers both by 
specialty, demographics, and practice characteristics. The sample size was small, making it hard 
to find differences between subgroups. Overall given the significant concern in bias in the 
measurement tool and its analysis the overall internal validity is poor and the results are limited 
in their able to provide information on physician screening style or physician knowledge of 
guidelines. The external validity was not assessed since the internal validity was poor. 
Guerra et al (2007/4 
In 2004 Guerra et al, conducted interviews of 18 purposively sampled physicians from 
the University of Pennsylvania Health System (UPHS) network. The interviews were semi-
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structured and were done by trained medical students within four months of each other. The 
interviews used chart stimulated recall to assist the discussion. The study aim was to determine 
barriers and facilitators to discussion of PCS. It did not try to determine PCS use. The interview 
guide was developed using the McPhee Systems Model and was pilot tested on faculty 
physicians.33 
Results 
All physicians reported generally using PSA discussion but 6 (33%) reported 
occasionally using PSA screening without discussions. Three explained that they would order 
PSA if not able to have a discussion because of liability concerns and perceived local standard of 
care. Two thirds reported they would initiate discussions at age 40 for higher risk men (family 
history or African American). Physicians reported lack of time and visits for other reasons 
besides physicals as another barrier to discussing PSA. Four providers also reported their own 
forgetfulness as a reason why the discussion did not occur. Physician, patient and system 
barriers and facilitators were identified that affect PSA discussion. Due to the small size 
statistical analysis could not be done. The study did not assess physician knowledge of 
guidelines. 
Quality, Strengths and Weaknesses 
Overall the internal validity of the study was fair. The validity of the measurement tool 
and the outcome were both well done. As a qualitative study the use of triangulation, a 
standardized and validated interview guide, transcripts of all interviews, and trained interviewers 
were all strengths. The results were grouped into categories with common or repeated responses 
noted. The use of chart stimulated recall allowed for a better understanding of provider practice 
beyond their reported practice. The study was unable to be statistically analyzed because of the 
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small study size resulting in limiting the understanding of the significance of the results. The 
external validity of the study was fair. The small sample size and academic, urban and suburban 
provider population were significant limitations to the generalizabilty to rural and community 
physicians. Purposeful sampling increased the diversity within the study group and its 
generalizability to academically connected physicians. 
Bell et al (2006/ 1 
In 2005 Bell et al conducted a survey of 70 randomly sampled primary care providers in 
the Los Angeles, CA area. The purpose of the study was to develop a knowledge test related the 
USPSTF prostate cancer screening recommendations. The survey also covered attitudes and 
practices related to prostate cancer screening. Experts in the field for content validity reviewed 
the survey questions. The survey was web-based and physicians were contacted by email and 
phone for recruitment. Seventy physicians completed the survey and were eligible out of the 285 
who were contacted. The physicians were diverse in ethnicity, practice setting, and were divided 
between family practice, general practice and internal medicine. 
Results 
Sixty percent of physicians reported using shared decision-making. Physicians who were 
board certified, had teaching affiliation or were within 20 years of medical school graduation had 
higher knowledge scores. The average knowledge scale score was 13.7 correct out of30. The 
physicians with higher knowledge scores had an inverse relationship with belief in PSA 
screening (rating of -0.49 on -1 to 3 scale). No other variable had significant association with 
belief in PSA other than knowledge. Routine PSA use was found to be common with an average 
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score of 6.7 out of 10 (10 was for high use in all men over age 40). The study did not assess 
knowledge of guidelines other than USPSTF. 
Quality, Strengths and Weaknesses 
Unlike the other studies included in this review, the main purpose was to develop the 
knowledge scale based on the USPSTF guideline. The overall internal validity ofthe study was 
fair. The survey was not pilot tested on primary care providers prior to sending it out, though it 
was review by experts in the field for internal validity. The results of the knowledge survey were 
internally consistent and they corresponded to the expected results of the PSA screening practice 
part of the survey. Selection bias is unlikely since physicians were randomly chosen from the 
AMA registry for the Los Angeles area. Multiple possible confounders were controlled for 
including sex, years since graduation, specialty, practice type and age. The external validity of 
the study was fair. The study was limited by the small sample size and single large city, LA, 
making it less generalizable. 
Kim eta/ (2002/2 
Kim eta! conducted an internet-based survey of internal medicine (IM) physicians (from 
a national list) and family practice physicians in New York, Illinois, and North Carolina. The 
survey was 18 questions long and was evaluated for internal validity through review by 2 
urologists and 1 PCP. The purpose of the survey was to determine the practice patterns of 
physicians in regards to prostate cancer screening and management of BPH. 
Results 
Three hundred and fifty four physicians participated in the survey. A total of 49% of all 
PCP recommended PSA screening in men over age 50 with more FP physicians recommending it 
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compared to IM physicians. No significant differences in practice pattern were seen by sex. 
Another 17% of physicians (IM and FP) report not recommending prostate cancer screening at 
any age. It did not assess knowledge of prostate cancer screening guidelines. 
Quality. Strengths and Weaknesses 
The internal validity of the study was fair. Selection bias is possible since it is unclear if 
all physicians with listed email addresses in the base population were recruited. The 
measurement tool could also have some bias. Only three physicians reviewed it during 
development, and the final version was not reviewed prior to use. The results were reported as 
physician practice when they are in fact physicians reported practice, which may differ from 
their actual practice pattern. Analysis was done looking at differences between screening styles 
by provider specialty. Confounding was only looked at for provider sex and other confounders 
(year since graduation from medical school, academic affiliation, knowledge, etc) could also 
affect screening styles. The external validity of the study was good. The larger base population 
and the more geographically diverse population make the results more generalizable. 
Philips et al (2005y27 
Philips et a! conducted a cross-sectional study on prostate cancer and colon cancer 
screening practices of primary care providers. Two surveys were mailed to 416 Vermont family 
practice and general practice physicians over a three-month period in 2003. The first survey 
focused on prostate cancer and the second on colon cancer screening. The purpose of the survey 
was to assess physician attitudes, behavior, and underlying reasons for screening behavior. It 
was also designed to determine whether patients or physicians are driving PSA-based screening. 
Results 
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The study found that 99% of physicians report routinely counseling on prostate cancer 
screening and 69% report routinely screening for prostate cancer. Most physicians ( 61%) feel 
that counseling is satisfactory for informed decision-making. Only 12% (10% unsure, 2% felt 
prostate cancer had stronger evidence) of physicians did not know that colorectal cancer 
screening has stronger evidence than prostate cancer screening. Sixteen percent of physicians 
were found to start prostate cancer screening with PSA before age 50 and 57% screen with DRE 
before age 50. An additional29% of physicians never stop PSA screening and 60% never stop 
DRE. Physician age and having a close contact with prostate cancer was not found to affect 
screening practice or belief. Specific knowledge of guidelines was not assessed though 
aggressive screening was defined by current guidelines. 
Quality, Strengths and Weaknesses 
Its internal validity was poor since it failed to report enough information about the 
methods to allow for a full quality evaluation. No information was reported on how the survey 
was developed. It is unclear how many questions were on the survey and what the questions 
were. The timing of the mailings was also not reported but is important since information was 
provided on prostate cancer with the second mailing. Selection bias is unlikely since the 
Vermont medical board provided the list of physicians who were contacted. The analysis looked 
at some provider characteristics, which could influence screening behavior including age and 
having a close contact with prostate cancer. It did not look at other possible confounders 
including race and sex. External validity is unable to be assessed due to poor internal validity. 
Purvis Cooper et al (2004/6 
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Purvis Cooper et a1 conducted a qualitative study using focus groups composed of 4 to 8 
IM, FP or general practice physicians. A total of 14 focus groups were done including a total of 
75 physicians from 35 different states. A professional moderator with extensive experience ran 
the focus groups. The focus groups were done via telephone in December 200 I and January 
2002. The physicians were selected for recruitment by a random sample of 1000 physicians in 
the AMA registry. The discussion was focused around physicians PSA screening practices, the 
influences on theses practices and their familiarity with clinical practice guidelines related to 
PSA screening. All discussions were transcribed and triangulation was done of the data. 
Results 
Two groups of physicians emerged: those who routinely screen with PSA (n=58) and 
those who are not routine screeners (do not routinely order PSA tests) (n=l4). Most "routine 
screening" physicians recommended use ofPSA in men 50 or older with a longer than 10 year 
life expectancy and no risk factors. "Non-routine screeners" typically discuss the implications 
related to screening prior to offering the PSA test. The majority of these physicians did not offer 
recommendation to their patients as to whether or not they should be screened. "Routine 
screeners" cited their experience and patient expectations as major reasons why they routinely 
screen. Only a few could accurately describe the current clinical practice guidelines. "Routine 
screeners" were also more likely to cite concerns about perceived community standard of care, 
concerns of malpractice, and practicing "comprehensive" medicine as moderate reasons why 
they screen. 
"Non-routine screeners" were all aware of clinical practice guidelines and could describe 
them mostly accurately. They were more likely to cite lack of scientific evidence as the major 
reason why the do not routinely screen and to report practicing evidence-based medicine as a 
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moderate reason for their practice style. Cost considerations and mandates from payors or 
practice settings were minor concerns for both groups of physicians. 
Quality, Strengths and Weaknesses 
The internal validity of this study was good. It is large enough and diverse enough that 
saturation of themes is likely to have occurred. Selection bias is unlikely. The participants were 
randomly selected participants from across the country. An analysis showed the study 
participants differed from the AMA master file only in that fewer were specialized in Internal 
Medicine compared to FP or General Practice. The data analysis was done in a systematic way 
using qualititative data software, coding and multiple coders to decrease possible bias. The 
results were consistent with prior research though they more clearly defined differences between 
physicians who are routinely screening and those who are not. The external validity of the study 
was also good given the adequately sized nationally representative sample of physicians making 
the results generalizable. 
Overall Results and Conclusions from the Systematic 
The overall strength of the evidence looking at whether physicians are currently 
using shared decision-making for prostate cancer screening and whether they have knowledge of 
the CPGs regarding prostate cancer screening is weak. No cohort or case-control studies were 
found. The studies as a whole were mainly focused on urban and academically affiliated 
physicians making them poorly generalizable to community physicians. The majority of the 
studies were on small mostly nonrninority physicians. None of the studies were of high quality. 
Five of the seven studies identified through this review are offair quality, the other two are of 
poor quality. No studies validated the physician reported practice through a parallel patient 
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survey allowing for nondifferential measurement bias to be a concern for all of the studies. Given 
that physicians do not have a clear ICD9 code to use to report the use of shared-decision-making 
to not screen a patient, interviewing both the physicians and their patients is the only way 
(besides video taping the encounter) to gain an accurate picture of the use of shared decision-
making for prostate cancer screening. Although chart reviews may give an estimate of the use of 
shared decision making, they may have low accuracy. For example, one study looked at medical 
records and it found a large discrepancy between physician reported practice and physician's 
written practice. The study by Guerra et al found all physicians reported generally having 
discussion but only 3 6% of the time were discussion documented in the medical record. 34 While 
that study was too small for statistical analysis, it does highlight the possible bias of physicians 
to over-report using shared decision-making. Further studies need to be done to assess this and 
whether it is even higher for physicians who are aware of the CPGs since they may want to 
report what they know is the "correct" answer. Confounding is a significant concern for three of 
the studies since Edlefsen showed that provider characteristics, (year since graduation from 
medical school, gender, and mode of reimbursement) do affect self-reported PSA use?6 Kim et 
al only controlled for provider sex, 32 and Philips et al controlled for age and having a close 
contact with prostate cancer but nothing else.27 Linder et al did not report controlling for any 
possible confounders. 28 Only the studies by Pendelton and Bell controlled for multiple 
confounders.31 ' 35 
Though several studies have been published in the last few years, only two, Purvis 
Cooper et al and Bell et al, were found that looked at any clinical practice guideline knowledge 
since the year 2000. Bell tested physician knowledge based on the USPSTF guideline and Purvis 
Cooper asked during the interviews about CPGs. 31 • 36 Given that clinical practice guidelines 
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are developed with the goal of influencing clinical practice, the paucity of studies considering 
their effect shows a need for future research. 
The current evidence, though too weak for conclusions to be drawn, can be used as a 
basis to determine trends in reported practice and needs for where future research should be 
focused. Five of the seven studies included in the review found that most physicians report 
·d· I 1. , · 21 2s 31 34·36 B 61 prov1 mg at east some pretest counse mg ,or prostate cancer screenmg. ' ' ' etween 
and I 00% of physicians reported having prescreening discussions or using shared decision-
making for prostate cancer screening. 27• 28• 31 Even in studies where most physicians report 
using shared-decision making, some physicians report routinely or occasionally ordering PSA 
without discussions, 30• 33 ' 35 The majority of physicians in all of the studies report having 
prescreening discussions for prostate cancer. Many also admit when asked, that they do not 
always have them and Guerra showed that they documented doing it only 36% of the time.34 
It is unclear what the content is of those physician led discussions on prostate cancer 
screening since none of the studies addressed this. Are physicians who are having discussions 
truly practicing shared-decision making where the patient is not biased by the physician's 
opinion or are physicians influencing their patients based on the content of the discussion? One 
study, Linder eta!, reported 32% recommend screening and II% of physicians would try and 
persuade patients who do not want PSA to have a PSA.Z8 If a physician is trying to persuade 
their patient either consciously or unconsciously based on the content they emphasize most 
patients will follow their physicians' lead. If physicians are failing to adequately counsel on the 
possible harms of prostate cancer screening including the cascade from an elevated PSA through 
the work up and treatment of benign tumors and false positive tests, then many patients may feel 
that it is simply the risk of a blood draw. Further, if physicians are not adequately counseling is 
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it from ignorance, choice, lack of time, internal clinical policies, or some other reason? While 
several of the studies looked at physician knowledge related to prostate cancer screening, none of 
the studies were done after the interim results of the randomized trials (PCLO and ERSPC) 
looking at the effect of PSA on mortality were published. Even though the results were not 
conclusive, they still represent the best evidence we have on the harms and benefits related to 
prostate cancer screening until their final results are released. What are physicians now saying 
and what have they been saying as the risks and benefits of prostate cancer screening to their 
patients? It is not likely by chance that none ofthe CPGs specify what should be included in the 
shared decision-making discussion other than "risks and benefits." 
Despite the uncertainty of risk or benefit, physicians are still asked to counsel their 
patients on what we do know and not to just order a PSA. Few studies directly assessed 
knowledge of clinical practice guidelines.31· 36 Physician knowledge of the unclear evidence for 
prostate cancer screening was found to be associated with higher adherence to the prescreening 
discussion and shared decision-making suggested in the current guidelines.31 · 34· 36 Physician 
belief that prostate cancer screening is beneficial or has clear evidence was found to be 
. d . h . . I 27 31 35 36 AI 2 d' h d 'd associate w1t more aggressive screemng sty es. · · · so stu 1es s owe provi ers are 
less likely to screen men who have multiple co-morbidities or are deemed to have a life 
expectancy of less than I 0 years. 34· 36 The results of the studies are mixed on whether 
physicians might knowledge of the guidelines. It is clear that physician knowledge of the 
uncertainty of benefit results in higher rates of discussion before ordering a PSA test. It is not 
clear whether these physicians also know the guidelines, or are by chance following them. 
The results show that physician knowledge of evidence related to the risks and benefits of 
prostate cancer screening are important in determining their practice style. Further a physician's 
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ability to counsel their patients about prostate cancer screening will be by nature limited by their 
own knowledge. While few studies directly assessed knowledge and compliance with CPGs 
several indirectly looked at it. Physicians are screening the recommended groups of men more 
frequently than men of other ages or risks. 34• 36 The results also imply that some physicians are 
unable to adequately counsel their patients on the risks and benefits of screening because they do 
not correctly understand them themselves based on their answers on knowledge questions?7• 31 • 34• 
36 
We will use this information to develop a survey, which will assess both provider 
reported practice and provider knowledge of the CPGs and the current evidence on the risks and 
benefits of prostate cancer screening (the randomized trial intermediate results published in 
NEJM in 2009). We will develop a survey, which distinguishes between providers who test 
without discussing and providers who discuss and offer testing. We will ask providers to first 
report their knowledge of CPGs and the randomized trials and then ask a knowledge question to 
confirm their report. We will ask providers to specify whether they weigh the harms or benefits 
higher (or equal) when discussing prostate cancer screening to gain some insight into the content 
of their discussion. 
Original Research Study Design 
Population and Recruitment 
All family practice and internal medicine physicians in the State of North Carolina who are 
members of the North Carolina Medical Society (NMCS) will be eligible for the survey. 
Approximately 2664 family practice physicians and internal medicine physicians will be invited 
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to participate by an email sent through the NCMS. Physicians will also be recruited through a 
short ad included in two mailings of the NCMS weekly newsletter 
Survey Tool 
We will conduct a cross-sectional survey to assess current provider knowledge of 2008 
Prostate Cancer Screening guidelines, knowledge ofPLCO and ERSCP randomized trials and 
current practice and beliefs in regards to use ofPSA. The 25-question survey was developed 
using The Tailored Design Method from Dillman.38 Five questions on provider screening style, 
separating physicians into Discussing or Not Discussing, were adapted with permission from the 
survey by Linder et al.28 The survey will ask demographic information including sex, age, race, 
provider specialty, practice type, practice location and personal prostate cancer history. Based 
on the results from a study by Drummond et al on ordering of survey questions, the demographic 
information will come first. 39 The survey will ask providers on their awareness of the 2008 and 
2009 changes in prostate cancer screening guidelines and the 2009 prostate cancer screening 
mortality studies (PCLO and ERSPC). It will test this knowledge by asking providers to answer 
a few questions about both the guidelines and the papers. It will further ask whether or not their 
practice has been influenced by the new mortality studies and the provider's current belief as to 
the benefit of screening 
The survey will be piloted on 8 physicians associated with the UNC Preventive Medicine 
Residency, 6 of whom are BC/BE each in one in of the following fields of medicine: family 
practice, geriatrics, gastroenterology, pediatrics, preventive medicine, and oncology. The other 
two resident physicians have preventive medicine as their main specialty. Any comments or 
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suggestions will be considered and the survey will be adapted as needed and again reviewed by 
two of the same group of physicians prior to sending it out. . 
The survey is located on a secure website (www.gualtrics.com) with emails sent 
containing links to the survey. A link to the survey and invitation to the study will also be 
included in two editions of the NCMS newsletter. A cover letter will be sent with the email. 
The consent letter will be posted at the website for participants to view before proceeding to the 
survey. The email and newsletter postings will be sent every 2 weeks starting with the email 
(email beginning of week I, newsletter beginning of week 3, newsletter beginning of week 5). 
Incentive 
Based on the report in Dillman of a doubling of response rate from approximately 40% to 80% 
for a physician survey when a $1 0 incentive was included in the initial mailing we felt an 
incentive would be beneficial to our response rate. Our study will offer a drawing for 28, $50 
gift cards for Amazon.com. If the anticipated 30% of physicians respond (799) then participants 
will have a 1121 chance of winning a gift card. The drawing will be done to include all 
physicians who give a way of contacting them with the results of the drawing approximately 2 
weeks after the last notice is sent in the NCMS newsletter. 
Measures 
Main Measure of Interest: Difference in provider belief of benefit of prostate cancer screening 
between providers with knowledge of at least one of the mortality studies compared to providers 
without knowledge of the mortality studies. 
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Secondary measure of interest: Provider reported practice style, provider knowledge of mortality 
studies, and provider knowledge of guidelines. 
The results will be controlled for possible confounders including: difference in provider location 
(region ofNC), practice type, years of medical practice, provider race (minority versus white), 
gender, specialty, and personal experience with prostate cancer. Any significant difference 
between providers' knowledge, beliefs or reported practice style based on a demographic or 
descriptive characteristics will be reported. 
Statistical analysis 
The study population and size was selected based on a power calculation to allow a 10 percent 
difference between physicians belief of benefit from prostate cancer screening for physicians who 
know of at least one mortality study compared to those who know neither study, with a power of 
0.8, alpha of0.05. A population of 193 physicians needs to be aware of the studies, which based 
on an estimated 20% response rate to the invitation to the study and an estimated 40% of 
respondents having knowledge of the mortality studies, the study population size (2664) will be 
sufficient. The power calculation was based on this part of the study as the proportion of 
physicians with knowledge of the mortality studies is expected to be much lower than the 
proportion with knowledge of at least one guideline. 
Descriptive statistics will be tabulated for all of the physicians participating in the study. 
Categorical variables will be compared using chi-square analysis and Fisher's exact tests. T-tests 
and one-way analysis of variance (ANOV A) will be used to test for differences in the means for 
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continuous variables. For all statistical tests, statistical significance will be set at a p value of 
0.05 using two-tailed tests. The statistical analysis will be performed using the Stata 10 
software. 
Result Tables 
Table 1. Provider Characteristics 
Demographic Info Value 
Mean Age (SD, median) 
Sex, n(%) 
Male 
Race, n(%) 
White 
Black 
Other 
Medical specialty, n(%) 
Family practice 
Internal medicine 
Mean Years since finishing 
residency (SD, median) 
Practice setting, n(%) 
Academic practice 
Community clinic 
Personal/Close contact with 
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I Prostate Cancer, n(%) 
Table 2. Physician Knowledge and Belief 
Physician Screening Style % Discussing 
Knowledge of Guideline: Yes+ correct, Yes + incorrect No 
Any Answers answers 
USPSTF 
ACS 
AUA 
AAFP 
Knowledge of Mortality 
Studies: 
Any 
ERSPC 
PCLO 
Table 3. Mortality Study Knowledge, Influence 
Know 1 or more Do Not know 
study + correct mortality study or 
incorrect on both 
Provider type (%) 
Family practice/Internal medicine 
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Discussing/ Not Discussing 
BeliefofBenefit:% (95% Cl)** 
More beneficial than harmful 
More harmful than beneficial 
Unsure 
Equal 
Change in Practice because of study (%) 
Discuss more harms 
Discuss more benefits 
No Change 
Unsure 
Method for Learning of Studies 
News 
Read Article/CME 
Colleague 
Related articles 
¥*controlled for age, sex, race, history of prostate cancer m self or close fnend/relat1ve, 
knowledge of guidelines 
Discussion 
Primary care providers are tasked with providing preventive health care services for their 
patients including having a discussion with their patients to allow them to make an informed 
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decision on their preferences for Prostate Cancer screening. The complexity of the debate about 
the benefits and harms associated with prostate cancer screening make educating patients 
challenging. Yet most providers follow the guidelines and report doing shared decision making 
with their patients regarding prostate cancer screening. What information a provider gives 
during a discussion is limited by their knowledge. 
If physician knowledge of at least one guideline and at least one mortality study is found 
to be associated with physicians having a discussing screening style compared to physicians with 
knowledge of only the guidelines then it will show that the mortality studies are influencing 
practice. The association between knowledge of a mortality study and physician screening 
practice will be further looked at by physician reported influence of the studies. Whether or not 
physicians report the mortality studies altering their screening practice and in what way will help 
determine whether an association or lack of association between screening styles and knowledge 
of the studies is truly present. Overall belief that prostate cancer screening is more beneficial 
than harmful or more harmful than beneficial will also be compared between providers with 
knowledge of the mortality studies and those without. If there is an association between belief of 
benefit or harm of screening and knowledge of the mortality studies it will also imply that the 
studies have impacted clinical practice. It is unlikely that the mortality studies are affecting 
clinical practice if physicians report that it is not and there is no association between knowledge 
of the mortality studies and physician screening style or physician belief in benefit or harm. 
If an association is found between knowledge of the mortality studies and physicians 
being discussing providers, physicians believing in benefit or harm of prostate cancer, or 
physicians altering the content of their prescreening discussions then it will show the importance 
of increasing dissemination of the studies. If no association is found between knowledge of the 
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mortality studies and provider screening type, provider belief in benefit or harm of prostate 
cancer screening, or provider reported content of counseling then the extent of dissemination of 
these studies will be less important. 
Further if the majority of providers are not aware of the mortality studies making it 
difficult to determine association between knowledge and physician screening characteristics, 
then it will show an area where further dissemination of the studies can be targeted. Analysis 
will be done to determine ifthere is a subgroup with significantly higher or lower knowledge 
than another helping to show where targeted dissemination efforts can be done. The same is true 
if they have inaccurate knowledge by being familiar with the studies but having incorrect recall 
of the results. If the study finds that the majority of providers are aware of the mortality studies 
then it will imply that successful dissemination of the information has occurred. 
How physicians with knowledge of the studies report learning about them can be used to 
look for an association between physician knowledge and the news media dissemination 
compared to medical journal dissemination. The US news media had an emphasis on the 
negative or no benefit results of the mortality studies. If physicians report reading the journal 
articles but think that both studies found no benefit in mortality then it suggests that the US 
media may have influenced their perception of the articles. A study would need to be done to 
show if physicians' perception of the mortality studies is influenced more by the news reporting 
of the study than by the actual journal article on the study. 
Limitations 
Our study has several limitations. The first is possible selection bias as physicians who 
choose to be members of the NCMS and have e-mail access may be different than internal 
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medicine and family practice physicians who are not members or do not have e-mail access. 
Further, the response rate may be low and there may be a difference between those physicians 
who responded to the survey and those who chose not to. Further our study population is all 
from the state of North Carolina so it is not a nationally representative sample though it does 
include physicians from all regions of the state and in diverse practice settings. Second, like all 
cross-sectional surveys it is difficult to know how closely reported information mirrors reality. 
We did try to limit this by using a validated group of questions to determine practice style and by 
having knowledge questions on the guidelines and the studies. Physician reported knowledge 
though verified by knowledge questions could also be inaccurate since chance could allow for 
correct answers as well. Third, while the results of this study are able to show associations 
between knowledge and practice the study by design is unable to show causality between 
knowledge of the mortality studies and change in clinical practice. 
Public Health Implications and Future Studies 
Levels of physician knowledge of new clinical practice guidelines and new randomized 
controlled trial evidence will have important implications for professional education needs. 
Physician's reporting of how they learned their current knowledge will also have implications for 
methods of educational dissemination. Future research will need to be done in methods of 
dissemination for both CPGs and randomized control trial evidence. Particularly looking at 
evidence and guidelines that are either not clear or not major changes from current practice. 
Whether or not physicians have belief in benefit of PSA and whether or not they are 
counseling on both risks and benefits will have implications for the likelihood that physicians are 
influencing their patients to have PSAs done or not. If physicians are actually encouraging more 
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PSA tests then it has large public health implications given the cost, both in health and money, of 
treating the false positives. Philips et a! showed that physicians' beliefs whether for or against 
screening predicted whether their patients received PSA tests. 27 As long as the evidence remains 
unclear and physicians are tasked with counseling not recommending one course of action over 
another, their personal belief and knowledge will continue to affect their counseling. Further 
research needs to be done to understand the strength of this correlation. A study specifically 
assessing the content of pretest counseling is also needed to help determine if guidelines need to 
be more specific. 
Until the PCLO and ERSPC have released their final results we will be unable to 
determine ifthere is more benefit than harm from PSA screening. Important in the results from 
those trials will be the analysis looking at the complications for the false positives. Public health 
policy makers will need to weigh whether the benefits of a potentially modest reduction in 
mortality out weighs the harms from the false positives. Physician practice may need to be 
changed depending on the results of the randomized trials and depending on what current 
practice is. If physicians are already feeling like the harms out weigh the benefits and the final 
results of the study support the same conclusion but evidence lacks the strength to stop all 
screening then little may change. Whether or not screening is cost-effective is another important 
consideration given high prevalence of the disease and the large risk pool. Important influences 
on the cost -effectiveness are the chronicity and prevalence of many complications from 
treatment compared to the clinically insignificance of many prostate cancers. If the PCLO and 
ERSPC trials show net benefit than a cost effective analysis will be an important next step. 
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Email Invite 
Dear Colleague: 
We are conducting a research study to better understand primary care providers' current practice 
and beliefs about prostate cancer screening. A total of 2,664 primary care physicians in North 
Carolina have been chosen to participate in this study. Your participation in this study is 
completely voluntary. 
To participate, you would complete 25 questions addressing your current practice regarding 
prostate cancer screening, possible influences on that practice, and demographic information. 
Completion of the online questionnaire should take no longer than 10 minutes. 
Please read the consent below regarding the questionnaire and a drawing for $50 Amazon gift 
cards in appreciation of your participation. After reading the consent, you may proceed to 
*****website link****** to complete the survey. 
Thank you for considering participation in this study. We hope we can share your views with the 
greater professional community and use your response to help shape recommendations on 
prostate cancer screening. 
Sincerely, 
Tiffany Wedlake, MD, PGY3 
Preventive Medicine Resident 
UNC Chapel Hill 
Margaret Gourlay, MD, MPH 
Department of Family Medicine 
UNC Chapel Hill 
********************************** 
Consent 
Influences and Beliefs Regarding Prostate Cancer Screening 
Date 
Your participation in this questionnaire is anonymous. You are asked not to put any identifYing 
information on the questionnaire. All data obtained in this study will be reported as group data. 
No individual can be or will be identified. We plan on publishing the results of this research as 
well as communicating these results to the NCMS for distribution to their members. The only 
persons who will have access to these data are the investigators named on this letter. 
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Because we want to encourage the participation of as many physicians as possible, we will be 
also be posting a link to the survey on the NCMS website. If you complete this questionnaire, 
you can elect to participate in a random drawing to receive one of 38, $50 gift cards for 
Amazon.com. In order to receive the gift card/be entered in the drawing you will need to 
provide some form of contact information (phone number, address, or email address) in the 
separate question block offered at the end of the survey. Any contact information provided here 
will not be included in the data analysis and will only be used to distribute the gift cards; the 
contact information will not be linked to the survey response. All contact data will be erased 
after the drawing is complete (6 weeks after first e-mail is sent) and the gift cards have been sent 
out. But please note that participating in the drawing/incentive is completely optional. 
There are no anticipated risks or benefits to you if you participate in this study. However, there 
will be professional benefit, as the results of the study will be communicated to the profession 
through publication in the literature, presentation at professional meetings and direct 
dissemination to the professional associations. There is no cost to you and no guaranteed 
financial benefit for your participation. 
You may contact us with any questions at (919) 843-8267 or by email wedlake@email.unc.edu 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare. If you have questions or concerns about your rights as a research subject you may 
contact, anonymously if you wish, the Institutional Review Board at 919-966-3113 or by email 
to IRB subjectslalunc.edu. 
*****survey website link******* 
Linder, 
Hawley, 
Cooper, I Cross-
Scholl, jibaja- sectional, 
Weiss, and 
Volk 2009 
Pendleton, 
Curry, 
Kaserian, I Cross-
Chang, Anai, sectional, 
Nakamura, 
Abdoush, and 
Rosser 2008 
Urban, university affiliated 
family practice clinics and 
urban community health 
centers, all located in 
Houston, TX 
• 87 recruited 
• 66 returned the survey 
• 3 excluded who either 
practice emergency 
medicine or psychiatry 
35 (53%) family practice 
28 ( 42%) internists 
Random sample of primary 
care physicians from 2 FL 
counties* (Duval and Alachua) 
• 264 recruited 
• 104 returned the 
survey 
• 6 excluded because not 
physicians 
60 (58%) family practice 
36 (35%) internist 
8 (8%) general practice 
Mailed Survey 
To determine provider 
reported use of prescreening 
discussion for use of PSA in 
age appropriate men: 
discussing (D) or not 
discussing (NO) 
And it looked for difference 
in use of PSA in high risk 
men 
Internet survey and hand 
delivered paper survey if 
non-responded after email 
invite. 
27 item questionnaire, 
accessing provider 
knowledge and practice 
regarding prostate cancer. 
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71.4% of physicians reported using 
prescreening discussions. 
NO providers more likely to order 
tests for high-risk patients (91% vs. 
46% 0 providers). 
Physicians who think PSA is 
beneficial more likely to persuade 
patients 
46% of physicians recommend 
screening to more than 75% of men 
>50 years old, 
66% of physicians believed prostate 
cancer screening is effective 
Physicians working in urban areas or 
serving minorities had higher 
knowledge scores 
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University affiliated primary Semi-structured interviews Physicians reported generally having care physicians* (University with chart stimulated recall 
of Pennsylvania Health discussions 
Guerra, System)** 30 to 45 minute interview by Only 36% of encounters had 
jacobs, Cross- trained medical student, documentation of discussions 
sectional, • 99 recruited received $50 for Holmes, and qualitative 18 participated participation, Shea,2007 • Time, physician forgetfulness, , 
• 1 excluded because of competing priorities of patient health 1 poor audio To determine barriers to 
physician discussion of PSA all were barriers for physicians 
testing with patients having discussions 
Random sample of urban 
primary care physicians from Online Survey Los Angeles, CA from AMA 60% of physicians reported using 
Bell, Hays, role 30 minute online survey, $75 shared decision-making 
Hoffman, Cross- 283 recruited reimbursement Physicians with higher knowledge • Day, Higa, sectional 70 participated about PCS had higher likelihood of 
and Wilkes, • To determine knowledge 
2006 questionnaire and beliefs of being either selective or low users of 27 (39%) family practice prostate cancer screening. PSA 39 (56%) internal medicine 
4 (6%) general practice 
Members of the Society of 
General Internal Medicine and 
members of the Illinois, North Internet survey 
Carolina, and New York 
chapters of the Academy of 18 item, 4-5 minutes 49% of FP jiM recommend PSA 
Kim, Benson, Cross- Family Physicians* screening for men over 50 with a Stern and 
sectional To determine practice higher proportion ofFP (67) vs. (40) Gerber 2002 • 1759 recruited patterns of physicians IM recommending screening with 
• 354 participated related to management of PSA 
prostate cancer (included 
113 (32%) family practice screening) and BPH 
238 (68%) general internists 
72%weremen 
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Family practice, internal 
medicine, and general 99% of physicians report routinely 
practice physicians in the counseling on prostate cancer 
rural state of Vermont, screening 
identified by the Vermont 2 Mailed surveys 
Philips, medical board. 69% report routinely screening for 
Reinier, Reported only that the first prostate cancer Cross- • 416 recruited Ashikaga, and 
sectional • 169 (40.6%) survey focused on prostate 61% report they feel counseling is Luebbers, cancer screening and the 
2005 participated second colon cancer satisfactory for informed decision-
screening. making 80 (50%) family practice 88% felt evidence stronger for 
75 (47%) general internists, colo rectal cancer screening 
76 (46%) physicians 50-70yo compared to prostate cancer 
53 (33%) had someone close screening. 
to them with prostate cancer 
Random sample from AMA 
role of family medicine, 
internal medicine or general 
Two groups of practice were found: practice physicians from 35 
states* Physician Focus groups one who routinely screened men 
over 50 and one who educated on 
• 1000 recruited 14 telephone focus groups screening but neither recommended Purvis for or against it. 
• 187 expressed interest were done including 6 to 8 Cooper, 
• 78 participated physicians each Merritt, Ross, Qualitative 64 did not meet The educating group reported john, and • uncertainty of evidence supporting inclusion criteria Discussion was done on PSA jorgensen, 
45 unavailable to screening practices, factors PSA use. 2004 • 
participate influencing these practices, The routinely screening group 
and familiarity with clinical 
reported patient demand and 51% family practice guidelines experience of benefit as reasons for 
33% internal medicine screening. 
16% general practice 
79% male 
84%white 
*did not report if population was urban or rural 
**due to small sample size of study and inability of study to do statistical analysis break down of provider type not included here 
Linder eta] 
2009 
Fair: selection bias - possible, reason for 
practice/physician selection not provided; 
confounding - possible, not controlled for or 
reported; measurement bias unlikely 
P dl Poor: measurement bias in survey and its en eton et j 1 . 1 · b" l"k 1 f d" a] 2008 ana ys1s, se ectwn 1as un 1 e y, con oun mg 
Guerra eta] 
2007 
Bell et al 
2005 
Kim et al 
2002 
Philips et al 
2005 
Purvis 
Cooper et al 
2004 
Fair: study population too small to allow for 
statistical analysis, purposeful sampling and 
Fair: measurement bias possible since survey 
was not piloted on any primary care physicians 
prior to use, selection bias unlikely, confounding 
Fair: some measurement bias possible since 
survey was only reviewed by 3 physicians prior 
to sending out and final version was not 
reviewed, selection bias is also possible since it is 
unclear how many of the eligible physicians in 
the population were recruited, confounding could 
be possible to account for the difference between 
but was not assessed 
Poor: unable to determine if measurement bias 
occurred due to lack of information about survey 
tool, selection bias unlikely since Vermont 
medical board identified providers for 
recruitment, provider characteristics were 
assessed for association with aggressive 
screening behavior making confounding less 
Good: selection bias, measurement bias unlikely 
since controlled for in design 
Fair: contains both internists and family physicians; 
not generalizable to community physicians 
Not assessed given poor internal validity. 
Fair: contained urban/suburban academic-based 
physicians making it less generalizable to community 
and rural 
Fair: all physicians were in Los Angeles area making it 
less generalizable to physicians in other locations 
especially small cities, towns or rural areas 
Good: large population from several areas of the 
country including both family practice and internal 
medicine physicians 
Not assessed given poor internal validity. 
Good: Large nationally representative sample 
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Please answer the following questions. 
Do you see male patients at least 50 years old for primary care? 
o Yes 
o No 
What is your primary speciality? 
o Family Practice Physician 
o Internal Medicine Physician 
o General Practice Physician 
0 Other (Please Specify) 
[ _________ ] 
Which year did you finish residency training? (YYYY) 
____ _j 
Which of the following best describe your practice setting? (mark all that apply) 
o Private Community Clinic 
o Academic Outpatient Clinic (associated with an Academic Medical Center) 
o Community/Migrant Health Center 
o Other (Please Specify) 
[ ______ _j 
Which North Carolina Area Health Region (AHEC) is your practice located in? 
0 Mountain (Buncombe, Cherokee, Clay, Graham, Haywood, Henderson, Jackson, Macon, Madison, McDowell, Mitchell, 
Polk, Rutherford, Swain, Transylvania, Yancey) 
0 Northwest (Alexander, Alleghany, J\she, Avery, Burke, Caldwell, Catawba, Davidson, Davie, Forsyth, Iredell, Rowan, 
Stokes, Surry, Watauga, Wilkes, Yadkin) 
0 Charlotte (Anson, Cabarrus, Cleveland, Gaston, Lincoln, Mecklenburg, Stanly, Union) 
0 Greensboro (Alamance, Caswell, Chatham, Guilford, Montgomery, Orange, Randolph, Rockingham) 
o Southern (Bladen, Cumberland, Harnett, Hoke, Moore, Richmond, Robeson, Sampson, Scotland ) 
o Wake (Durham, Franklin, Granville, Johnston, Lee, Person, Vance, Wake, Warren) 
o South East (Brunswick, Columbus, Duplin, Pender, New Hanover) 
o Area L (Edgecombe, Halifax, Nash, Northampton, Wilson) 
o Eastern (Beaufort, Bertie, Camden, Carteret, Chowan, Craven, Currituck, Dare, Gates, Greene, Hertford, Hyde, Jones, 
Lenoir, Martin, Onslow, Pamlico, Pasquotank, Perquimans, Pitt, Tyrrell, Washington, Wayne) 
11116/2009 I 0:45 AM 
Qual tries Survey Software http:/ /new .qualtrics.corn!ControlPanel/PopUp. php?PopType~SurveyPr ... 
2 of6 
Which sex are you? 
o Male 
o Female 
Which ethnicity are you? (mark all that apply} 
D White D Hispanic or Latino D African American or Black 0 Asian or Pacific Islander 
D American Indian/Alaska Native D Other 
Have you, a close family member, or a close friend ever had prostate cancer? 
o Yes 
o No 
For which age groups do you discuss (or offer) prostate specific antigen (PSA) testing to screen for prostate 
cancer in healthy asymptomatic men with normal risk (only risk factor age and sex)? 
Yes No 
-- --------- ---------- ------
<40 Years 0 0 
40-49 Years 0 0 
50-60 Years 0 0 
61-75 Years 0 0 
>75 Years 0 0 
Which approach best describes your practice regarding PSA screening with healthy age-appropriate men 
who have no other risk factors? (Check one) 
o I generally order the PSA test without discussing the possible harms and benefits with the patient. 
o I generally discuss the possible harms and benefits of PSA screening with the patient, and then recommend the test. 
o l generally discuss the possible harms and benefits of PSA screening with the patient, and then let him decide whether or 
not to have the test. 
o I generally discuss the possible harms and benefits of PSA screening with the patient, and then recommend against the 
test. 
o I generally do not order the PSA test nor discuss the possible harms and benefits with the patient. 
How often do you order the PSA test to screen healthy age-appropriate men who have no other risk factors? 
(Check one) 
o Never 
o Rarely 
o Some of the time 
o Most of the time 
0 
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Almost always 
o Always 
How often do you discuss the possible benefits of prostate cancer screening with healthy age-appropriate 
men who have no other risk factors before ordering the PSA test? (Check one) 
0 Never 
0 Rarely 
0 Some of the time 
0 Most of the time 
0 Almost always 
0 PJ.ways 
How often do you discuss the possible harms of prostate cancer screening with healthy age-appropriate 
men who have no other risk factors before ordering the PSA test? (Check one) 
0 Never 
0 Rarely 
0 Some of the time 
0 Most of the time 
0 Almost always 
0 Always 
Are your prostate cancer screening practices any different for African American men? (Check one) 
0 Yes, I am more likely to screen African American men for prostate cancer. 
o Yes, I am less likely to screen African American men for prostate cancer. 
o No, my screening practices are the same for African American men and other patients I see. 
Are your prostate cancer screening practices any different for men with a family history of prostate cancer? 
(Check one) 
o Yes, I am more likely to screen men with a family history of prostate cancer. 
o Yes, I am less likely to screen men with a family history of prostate cancer. 
o No, my screening practices are the same for men with a family history of prostate cancer compared to other patients I see. 
The following organizations have recently released updates of their guidelines on prostate cancer 
screening. Please mark the guidelines with which you are familiar. (mark all that apply) 
o American Academy of Family Practice (AAFP) updated guideline in 2008 
o American Urology Association (AUA) updated guideline in 2009 
o US Preventive Services Task Force (USPSTF) updated guideline in 2008 
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0 American Cancer Society (ACS) updated in 2008 
0 Other (Please Specify) 
L.._~---
0 None 
Please mark the following statements as true or false. 
The USPSTF guideline 
recommends against 
screening for prostate cancer 
in men under age 50. 
The USPSTF guideline 
recommends PSA tests for 
all men between age 50 and 
74. 
The USPSTF guideline 
recommends against 
screening for prostate cancer 
in men over age 75. 
The AAFP guideline 
recommends using patient-
provider shared decision 
making to determine which 
men between ages 50 and 
7 4 are screened with PSA. 
The AAFP guideline reports 
insufficient evidence to 
determine whether men 
between ages 50 and 7 4 
should be routinely screened. 
The AUA recommends 
offering PSA screening to 
well-informed men who are 
over age 40. 
The ACS guideline 
recommends using shared 
decision making and offering 
the PSA blood test and 
digital rectal examination 
annually to all men aged 45 
and older. 
All four of the guidelines 
recommend educating men 
about the limitations and 
benefits prior to doing 
screening for prostate 
cancer. 
True 
0 
0 
0 
0 
0 
0 
0 
0 
False 
0 
0 
0 
0 
0 
0 
0 
0 
Have you read or heard of the PCLO study resu~s published in March 2009 in the New England Journal of 
Medicine? (Randomized Prostate-Cancer Screening Trial by Andriola et al involving 76,000 men in the US) 
{mark all that apply) 
0 read the journal article or heard from a CME activity 
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0 heard or read in the news 
0 heard from a patient 
0 heard from a colleague 
0 read related journal articles 
0 not aware of the results/study 
Did it show a reduction in mortality from Prostate Cancer as a result of PSA screening and digital rectal 
exam? 
o Yes 
o No 
0 Don't Know 
Have you read or heard of !he ESPCM study results published in March 2009 in the New England Journal of 
Medicine? (Screening and Prostate-Cancer Mortality in a Randomized European Study by Schroder eta!. 
involving 162,000 men in seven European countries) (mark all that apply) 
EJ read the journal article or heard from a CME activity 
o heard or read in the news 
o heard from a patient 
0 heard from a colleague 
0 read related journal articles 
o not aware of the results 
Did it show a reduction in mortality from Prostate Cancer as a result of PSA screening? 
0 Yes 
o No 
o Don't Know 
As a result of either of these studies, do you feel the evidence FOR using PSA tests as a screening tool for 
prostate cancer is? 
0 Much Better 
0 Better 
0 About the Same 
0 Worse 
0 Much Worse 
o Not applicable (not familiar with the studies) 
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After learning about the results of the mortality studies, how have your prostate cancer screening practices 
changed? (mark all that apply) 
o I spend more time counseling on harms 
o I spend more time counseling on benefits 
0 I am more likely to order PSA without first discussing the risks/benefits with my patient 
0 I am less likely to order PSA tests without first discussing the risks/benefits with my patient 
o I did not change any part of my practice as a result of this evidence 
0 Not applicable (not familiar with the studies) 
Do you feel that Prostate Cancer Screening with PSA in aS1fmptc>ml!tic men between age 50 and 74 with 
more than a 10 year life expectancy is? 
o More beneficial than harmful 
o More harmful than beneficial 
0 Harms and Benefits are equal 
0 Don't know or Unsure 
Block 1 
11116/2009 10:45 AM 
